Personal information

Activities

Employment (2)

Fox Chase Cancer Center: Philadelphia, PA, US

2019-07-01 to present | Fellow (Hematology and Oncology)
Employment
Source: Self-asserted source
Benjamin Miron

Temple University Hospital: Philadelphia, PA, US

2017-06 to 2019-06-30 | Resident (Internal Medicine)
Employment
Source: Self-asserted source
Benjamin Miron

Education and qualifications (2)

New York University: New York, NY, US

2010-09 to 2014-06 | MD
Education
Source: Self-asserted source
Benjamin Miron

New York University: New York, NY, US

2003-09-01 to 2007-06 | BA
Education
Source: Self-asserted source
Benjamin Miron

Professional activities (1)

Urologic Oncology: Seminars and Original Investigations: Frisco, US

2019-04-01 to present | Reviewer
Invited position
Source: Self-asserted source
Benjamin Miron

Works (17)

Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles

Clinical Genitourinary Cancer
2024-12 | Journal article
Contributors: Anumita Chakraborty; Jill Hasler; Elizabeth Handorf; Fern Anari; Pooja Ghatalia; Benjamin Miron; Elizabeth R. Plimack; Daniel M. Geynisman; Matthew Zibelman
Source: check_circle
Crossref

Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer

ESMO Real World Data and Digital Oncology
2024-03 | Journal article
Contributors: B. Miron; G. Li; J.C.F. Quintanilha; A. Clark; T. Scott; J.S. Ross; G.R. Oxnard; L.W. Pasquina; R.P. Graf; S. Gupta
Source: check_circle
Crossref

The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression

Cancers
2023-12-06 | Journal article
Contributors: Agreen Hadadi; Harris B. Krause; Andrew Elliott; Jacqueline T. Brown; Bassel Nazha; Lara R. Harik; Bradley C. Carthon; Benjamin Miron; Chadi Nabhan; Pedro C. Barata et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

European Urology
2022-10 | Journal article
Part of ISSN: 0302-2838
Contributors: Benjamin Miron; Daniel M. Geynisman
Source: Self-asserted source
Benjamin Miron

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors

Urologic Oncology: Seminars and Original Investigations
2022-10 | Journal article
Part of ISSN: 1078-1439
Contributors: Benjamin Miron; Elizabeth Handorf; Kevin Zarrabi; Matthew R. Zibelman; Fern Anari; Pooja Ghatalia; Elizabeth R. Plimack; Daniel Geynisman
Source: Self-asserted source
Benjamin Miron

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma

The Oncologist
2022-10-06 | Journal article
Part of ISSN: 1083-7159
Part of ISSN: 1549-490X
Contributors: Kevin Zarrabi; Elizabeth Handorf; Benjamin Miron; Matthew R Zibelman; Fern Anari; Pooja Ghatalia; Elizabeth R Plimack; Daniel M Geynisman
Source: Self-asserted source
Benjamin Miron

Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer

Advances in Oncology
2022-05 | Journal article
Part of ISSN: 2666-853X
Contributors: Benjamin Miron; Jessica E. Hawley; Daniel M. Geynisman; Kent W. Mouw; John P. Sfakianos; Emily S. Weg; Fady Ghali; Jonathan Wright; Petros Grivas; Ali Raza Khaki
Source: Self-asserted source
Benjamin Miron

Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma

BMJ Case Reports
2022-05 | Journal article
Part of ISSN: 1757-790X
Contributors: Lauren Laderman; Omer Naveed; Carla LoPinto-Khoury; Efrat Dotan; Benjamin Miron
Source: Self-asserted source
Benjamin Miron

Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer

European Urology
2022-01 | Journal article
Part of ISSN: 0302-2838
Contributors: Benjamin Miron; Laura Bukavina; Elizabeth R. Plimack
Source: Self-asserted source
Benjamin Miron

Clinical and Functional Characterization of Atypical <i>KRAS</i>/<i>NRAS</i> Mutations in Metastatic Colorectal Cancer

Clinical Cancer Research
2021-08-15 | Journal article | Author
Part of ISSN: 1078-0432
Part of ISSN: 1557-3265
Contributors: Jonathan Loree; Yucai Wang; Muddassir A. Syed; Alexey V. Sorokin; Oluwadara Coker; Joanne Xiu; Benjamin Weinberg; Ari VanderWalde; Anteneh A Tesfaye; Victoria M. Raymond et al.
Source: Self-asserted source
Benjamin Miron

Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab.

Journal of Clinical Oncology
2021-05-20 | Journal article
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Contributors: Kevin Zarrabi; Elizabeth A. Handorf; Benjamin Miron; Matthew R. Zibelman; Fern Anari; Pooja Ghatalia; Elizabeth R. Plimack; Daniel M. Geynisman
Source: Self-asserted source
Benjamin Miron

Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond

Journal of Personalized Medicine
2020-11-13 | Journal article
Contributors: Benjamin Miron; David Xu; Matthew Zibelman
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

European Urology Oncology
2020-08 | Journal article
Contributors: Benjamin Miron; Jean H. Hoffman-Censits; Fern Anari; John O’Neill; Daniel M. Geynisman; Matthew R. Zibelman; Alexander Kutikov; Rosalia Viterbo; Richard E. Greenberg; David Chen et al.
Source: check_circle
Crossref

Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome

Molecular Oncology
2018 | Journal article
EID:

2-s2.0-85044458295

Part of ISBN:

18780261 15747891

Contributors: Kamal, M.; Tarcic, G.; Dureau, S.; Edelheit, O.; Barbash, Z.; Lecerf, C.; Morel, C.; Miron, B.; Callens, C.; Servant, N. et al.
Source: Self-asserted source
Benjamin Miron via Scopus - Elsevier

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer

Journal of Thoracic Oncology
2017 | Journal article
EID:

2-s2.0-85016814371

Part of ISBN:

15561380 15560864

Contributors: Peled, N.; Roisman, L.C.; Miron, B.; Pfeffer, R.; Lanman, R.B.; Ilouze, M.; Dvir, A.; Soussan-Gutman, L.; Barlesi, F.; Tarcic, G. et al.
Source: Self-asserted source
Benjamin Miron via Scopus - Elsevier

Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer

Urology Case Reports
2016 | Journal article
EID:

2-s2.0-84983548324

Part of ISBN:

22144420

Contributors: Miron, B.; Ristau, B.T.; Tomaszewski, J.J.; Jones, J.; Milestone, B.; Wong, Y.-N.; Uzzo, R.G.; Edmondson, D.; Scott, W.; Kutikov, A.
Source: Self-asserted source
Benjamin Miron via Scopus - Elsevier

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

Cancer
2011 | Journal article
EID:

2-s2.0-79952847624

Part of ISBN:

0008543X 10970142

Contributors: Ilson, D.H.; Kelsen, D.; Shah, M.; Schwartz, G.; Levine, D.A.; Boyd, J.; Capanu, M.; Miron, B.; Klimstra, D.
Source: Self-asserted source
Benjamin Miron via Scopus - Elsevier

Peer review (2 reviews for 2 publications/grants)

Review activity for Clinical genitourinary cancer. (1)
Review activity for The oncologist. (1)